Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510764 | 0.94 | FFAR1 (0.43) | FFAR1CYSLTR2CYSLTR1MAPTRXFP1 | |
| SCHEMBL4510771 | 0.94 | FFAR1 (0.43) | FFAR1CYSLTR2CYSLTR1MAPTRXFP1 | |
| SCHEMBL7007227 | 0.90 | LTA4H (0.38) | FFAR1CYSLTR2CYSLTR1S1PR1FAAH | |
| SCHEMBL4511480 | 0.84 | KMT2A (0.42) | MAPTS1PR1FAAH | |
| SCHEMBL3484621 | 0.84 | KMT2A (0.42) | MAPTS1PR1FAAH | |
| SCHEMBL3485099 | 0.84 | KMT2A (0.42) | MAPTS1PR1FAAH | |
| SCHEMBL3485095 | 0.84 | KMT2A (0.42) | MAPTS1PR1FAAH | |
| SCHEMBL3484620 | 0.84 | KMT2A (0.42) | MAPTS1PR1FAAH | |
| SCHEMBL4492263 | 0.84 | KMT2A (0.42) | MAPTS1PR1FAAH | |
| SCHEMBL4511488 | 0.84 | KMT2A (0.42) | MAPTS1PR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | TNNI3, TNNT2, FABP3 | FFAR1 2321/4885CYSLTR2 2415/4885CYSLTR1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.